Deprescribing of Diabetes Regimens in Long Term Care Residents With Alzheimer's

NCT05535478 | Completed DMC

• 1 other identifier: Pro00053280
• Study Type: interventional
• Target: 130
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives To 1) examine the ability of the STRIDE (Simplification of Treatment Regimens and Individualized Diabetes Education) educational program to increase deprescribing of high hypoglycemia risk glucose-lowering medications (HRMs) among long term care facility (LTCF) residents with ADRD, 2) assess key implementation constructs (secondary outcomes) of the STRIDE program, including acceptability, appropriateness, and feasibility, and 3) validate the primary HRM use outcome measure.

Conditions

Diabetes; Dementia; Hypoglycemia; Drug

Keywords

older adults; long term care facility; high risk medications; hypoglycemia; deprescribing; diabetes; dementia

Outcome Measures

Primary Outcomes (1)

• Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) use

  HRM use will include any sulfonylurea use (i.e., glyburide, glipizide, glimepiride, or chlorpropamide) and any insulin use.

  Baseline vs 6 months

Secondary Outcomes (3)

• Acceptability of the STRIDE Educational Program

  6 months

• Appropriateness of the STRIDE Educational Program

  6 months

• Feasibility of the STRIDE Educational Program

  6 months

Study Arms (1)

STRIDE Intervention

OTHER

Educational intervention for clinicians

Behavioral: STRIDE

Interventions

STRIDE BEHAVIORAL

a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls

STRIDE Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinical staff at the LTCF (MDs, PAs, NPs, clinical pharmacists) - (Targeted providers for STRIDE program)
• Clinical staff that participated in the STRIDE program (Providers doing stakeholder exit interviews)

Sponsors & Collaborators

• Joslin Diabetes Center: lead
• Brown University: collaborator
• Theoria Medical: collaborator

Study Sites (1)

Joslin Diabetes Center

Boston, Massachusetts, 02215, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus; Dementia; Hypoglycemia

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• Medha Munshi, MD

  Joslin Diabetes Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2022
• First Posted: September 10, 2022
• Study Start: January 31, 2023
• Primary Completion: July 14, 2025
• Study Completion: July 14, 2025
• Last Updated: July 30, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)